Barrons.com1d agoneutral
AstraZeneca-Bristol Myers: The Floodgates for Biotech Mergers Are OpenEven if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
527last 24h
2509last 7d
482● bullish (7d)
257● bearish (7d)
197publishers
PA Media: Money1d agoneutral
Stocks mixed as AstraZeneca merger talk dents FTSE 100The FTSE 100 index closed down 10.35 points, 0.1%, at 10,857.70.
MT Newswires4d agoneutral
AbbVie Trims Full-Year Profit Outlook Due to Apogee AcquisitionAbbVie (ABBV) lowered its full-year earnings guidance on Friday to account for the expected dilution
Motley Fool16d agoneutral
How Will AbbVie's $10.9 Billion Acquisition of Apogee Impact Its Dividend?There's no need to panic.
Quartz44d agoneutral
AbbVie acquires Apogee Therapeutics for $10.9 billionThe all-cash deal gives AbbVie access to zumilokibart, an experimental drug that could rival Dupixent in treating atopic dermatitis